MedPath

Surgical Intervention for the Treatment of Diabetes in Overweight Non-responders-1

Conditions
Overweight
Diabetes Mellitus, Type 2
Interventions
Procedure: Sleeve Gastrectomy with Ileal Transposition
Procedure: Sleeve Gastrectomy with Transit Bipartition
Other: Medical Treatment
Registration Number
NCT02610530
Lead Sponsor
Turkish Metabolic Surgery Foundation
Brief Summary

The SIT-DOWN study is a single centered retrospective study in which a total of 90 (ninety) participants who are overweight (BMI: 25-29.9 kg/m2) and have type 2 diabetes mellitus (T2DM) will be evaluated for the efficacy of surgical intervention in comparison with medical treatment. Primary endpoint of the study will be the change in glycemic regulation by the end of 12 months.

Detailed Description

Use of bariatric/metabolic surgery has conventionally been reserved for those whose body-mass index (BMI) is 35 kg/m2 or greater. Trials in these morbidly obese patients confirmed the benefits in terms of weight loss and provide evidence that surgery can result in remission of diabetes, and as a result lead to improvement in cardiovascular risk factors. Within the light of these data, there appear to be a shift towards lower BMI, with many advocating it as a reasonable option for diabetics with a lower BMI (\<30) who have failed other attempts of medical treatment. But this approach is limited because of lack of data on the effects of surgical outcomes in this group of patients which is the main rationale for this retrospective study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Overweight, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI= 25-29.9 kg/m2
  • Participants with baseline HbA1c ≥ % 7.5, not achieved HbA1c < % 7.3 at 3 months on therapy
  • Absence of co-morbidities (neuropathy, retinopathy, cardiovascular disease, stroke events or lower extremity amputation).
Exclusion Criteria
  • Liver cirrhosis, severe renal failure, collagen diseases, severe endocrinopathies, blindness.
  • Heart failure, acute myocardial infarction, stroke or transient ischemic attack, unstable angina pectoris.
  • History of malignancy or malignant neoplasm in place, severe inflammatory complications, neurological or cardiovascular in act.
  • Pregnancy
  • Any conditions that at the discretion of the head of the study can represent risk to the participant or could affect the protocol results.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Surgery-ASleeve Gastrectomy with Ileal TranspositionOverweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with ileal transposition
Surgery-BSleeve Gastrectomy with Transit BipartitionOverweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with transit bipartition
Non-SurgeryMedical TreatmentOverweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2 who have been on medical treatment for glycemic control.
Primary Outcome Measures
NameTimeMethod
Reduction in glycated hemoglobin (HbA1c)1 year

Complete diabetic remission (HbA1c \< 6%) and partial diabetic remission (HbA1c= 6-6.5%) without medication.

Secondary Outcome Measures
NameTimeMethod
Hypertension Control1 year

Systolic blood pressure (BP) \<130 mm Hg and diastolic BP \<80 mm Hg, without medication.

Weight Control1 year

Amount of weight loss in kilograms.

Change in LDL (low-density lipoprotein) Cholesterol1 year

\<100 mg/dL, without medication.

Change in HDL (high-density lipoprotein) Cholesterol1 year

\>40 mg/dL, without medication.

Change in Triglycerides1 year

\<150 mg/dL, without medication.

© Copyright 2025. All Rights Reserved by MedPath